Grants

MT20-007: Effects of dual antithrombotic therapy using rivaroxaban and clopidrogrel on platelet function and coagulation parameters in cats

Hypertrophic cardiomyopathy (HCM), a common heart disease in cats, can lead to severe, life–threatening disease such as heart failure or severe blood clots known as arterial thromboembolism (ATE). In humans, the use of multiple drugs to prevent thrombosis in at-risk patients is considered a superior treatment protocol to using a single agent therapy. The benefits of combining two preventative therapies, clopidogrel and rivaroxaban, requires further investigation in cats. This study proposes to compare the safety and effectiveness of single agent therapy of clopidogrel or rivaroxaban to the combined dual therapy with both drugs.

Grant ID: MT20-007

Status: Active

Year Funded: 2020

Amount awarded: $18,801

Investigator: Joshua Stern, Ronald Hak Long Li; University of California-Davis